Singapore - English - HSA (Health Sciences Authority)

aenon pharmaceuticals sea pte. ltd. - salmonella typhi (ty 21a berna strain) - capsule - not less than 2 x 10^9 viable organisms - salmonella typhi (ty 21a berna strain) not less than 2 x 10^9 viable organisms

New Zealand - English - Medsafe (Medicines Safety Authority)

biocelect new zealand ltd - salmonella typhi strain ty21a berna 2000 million organisms (minimum); salmonella typhi vaccine live attenuated 2000 million organisms (ty21a strain; minimum); salmonella typhi strain ty21a berna 2000 million organisms - modified release capsule - 2000 million organisms - active: salmonella typhi strain ty21a berna 2000 million organisms (minimum) excipient: ascorbic acid casein hydrolysate dibutyl phthalate diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate lactose fast flo iron oxide red iron oxide yellow lactose monohydrate magnesium stearate sucrose titanium dioxide active: salmonella typhi vaccine live attenuated 2000 million organisms (ty21a strain; minimum) excipient: ascorbic acid casein hydrolysate dibutyl phthalate diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate iron oxide red iron oxide yellow lactose magnesium stearate sucrose titanium dioxide active: salmonella typhi strain ty21a berna 2000 million organisms excipient: ascorbic acid diethyl phthalate erythrosine ethylene glycol gelatin hypromellose phthalate iron oxide red iron oxide yellow lactose magnesium stearate methanol methylene chloride protein hydrolysate sucrose titanium dioxide - vivotif oral is indicated for active immunisation against typhoid in adults and children above 6 years of age. effectiveness in children below 6 years of age is not known at present.

United States - English - NLM (National Library of Medicine)

paxvax, inc. - vibrio cholerae cvd 103-hgr strain live antigen (unii: v9g528e9e0) (vibrio cholerae cvd 103-hgr strain live antigen - unii:v9g528e9e0) - vibrio cholerae cvd 103-hgr strain live antigen 1200000000 [cfu] - vaxchora is a vaccine indicated for active immunization against disease caused by vibrio cholerae serogroup o1 in adults 18 through 64 years of age traveling to cholera-affected areas. the effectiveness of vaxchora has not been established in persons living in cholera-affected areas. the effectiveness of vaxchora has not been established in persons who have pre-existing immunity due to previous exposure to v. cholerae or receipt of a cholera vaccine. vaxchora has not been shown to protect against disease caused by v. cholerae serogroup o139 or other non-o1 serogroups. do not use in persons who have a history of severe allergic reaction (e.g., anaphylaxis) to any ingredient of vaxchora or to a previous dose of any cholera vaccine [see description (11)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to vaxchora during pregnancy. to enroll in or obtain information about the registry, please call paxvax at 1-800-533-5899. risk summary vaxch

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

patientric ltd - salmonella typhi strain ty 21a - gastro-resistant capsule

United States - English - NLM (National Library of Medicine)

emergent travel health inc. - salmonella typhi ty21a live antigen (unii: 0mzi008m96) (salmonella typhi ty21a live antigen - unii:0mzi008m96) - salmonella typhi ty21a live antigen 6000000000 [cfu] - vivotif (typhoid vaccine live oral ty21a) is indicated for immunization of adults and children greater than 6 years of age against disease caused by salmonella typhi . routine typhoid vaccination is not recommended in the united states of america. selective immunization against typhoid fever is recommended for the following groups: 1) travelers to areas in which there is a recognized risk of exposure to s. typhi , 2) persons with intimate exposure (e.g. household contact) to a s. typhi carrier, and 3) microbiology laboratorians who work frequently with s. typhi (7). there is no evidence to support the use of typhoid vaccine to control common source outbreaks, disease following natural disasters or in persons attending rural summer camps. not all recipients of vivotif will be fully protected against typhoid fever. vaccinated individuals should continue to take personal precautions against exposure to typhoid organisms. the vaccine will not afford protection against species of salmonella other than salm

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 7.5 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate; thiomersal - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: sodium chloride; dibasic sodium phosphate; monobasic sodium phosphate; potassium chloride; monobasic potassium phosphate; calcium chloride dihydrate; thiomersal - for active immunisation to prevent influenza disease caused by the influenza a (h1n1) virus, in persons from 6 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - clonazepam, quantity: 2 mg - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate; microcrystalline cellulose - most types of epilepsy in children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalised epilepsy, or to secondary generalisation of partial epilepsy. in adults, all varieties of generalised epilepsy (including myoclonic, akinetic, tonic and tonic-clonic seizures), and in partial epilepsy (including psychomotor seizures).